Headquartered in Grafenauweg 8, ZUG Fiscal year ends December NASDAQ: PHVS pharvaris.com
Pharvaris N.V. (Nasdaq: PHVS) is a late-stage, pre-revenue biopharmaceutical company developing oral therapies for rare diseases, initially bradykinin-mediated angioedema (AE-BK). This includes hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).
Its sole molecule, deucrictibant, is an oral small-molecule bradykinin B2 receptor antagonist being developed in two formulations:
- An immediate-release (IR) capsule for on-demand treatment of attacks. Its NDA is under FDA review with a PDUFA date of April 23, 2027, and an MAA is under EMA review.
- A once-daily extended-release (XR) tablet for prophylaxis. It succeeded in the pivotal Phase 3 CHAPTER-3 study, and an NDA submission is planned for 1H2027.
Deucrictibant holds orphan drug designation from the FDA, the European Commission and Swissmedic. The pivotal Phase 3 CREAATE study is evaluating it in AAE-C1INH.
The company reports under IFRS in euros and has funded itself through equity offerings, using equity-based incentives tied partly to regulatory milestones. It is building a commercial organization ahead of a potential first U.S. launch in 2027. Subsidiaries operate in the Netherlands, Switzerland and the United States. Updated
The wider loss is the cost of a launch build: general and administrative spending nearly doubled to $19.61 million as the company staffs up ahead of an April 23, 2027 FDA decision on oral deucrictibant. Cash of $313.94 million funds at least twelve months, but management says more financing is coming, so dilution is the live risk for a $2.4 billion pre-revenue biotech.
Pharvaris N.V. (Nasdaq: PHVS) is a late-stage, pre-revenue biopharmaceutical company developing oral therapies for rare diseases, initially bradykinin-mediated angioedema (AE-BK). This includes hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).
The Wall Street consensus 12-month price target for PHVS is $57.10.